← Leaderboards
Peter Westervelt
Washington University
$8,274,820
Attributed
$8,274,820
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $688.9K · FY2008–23$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,274,820 · 8
By mechanism
P01$3,850,770 · 3
P50$1,983,409 · 2
UG1$1,003,248 · 1
U10$937,080 · 1
K08$500,313 · 1
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- Timothy J Ley$36,060,228
- John F Dipersio$33,235,840
- Daniel C Link$19,842,999
- Matthew J Walter$8,261,626
- Timothy A Graubert$17,171,795
Others in their field
Top investigators on “Leukemia”
- Richard K. Wilson · Washington University$209,620,938
- David Heimbrook · Leidos Biomedical Research, Inc.$168,419,678
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Peter C Adamson · National Childhood Cancer Foundation$143,910,899
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$129,102,207
Research focus
LeukemiaProgramsWashingtonUniversitiesRelapseGenomicsBone MarrowSpecimenSkinCancer CenterBaseSerumPrognostic FactorLinkInstitutionCharacteristicsProtocols DocumentationEnrollmentTissuesGene ExpressionPeripheral BloodMolecularMalignant NeoplasmsPathogenesis
Grant awards (45)
Core A - Clinical Database.$350,344
P01 · FY2023 · CA · contact PI
Core A - Biospecimen Processing.$118,315
P50 · FY2023 · CA · contact PI
Core A - Clinical Database.$332,134
P01 · FY2022 · CA · contact PI
Core A - Biospecimen Processing.$186,281
P50 · FY2022 · CA · contact PI
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.$165,722
UG1 · FY2022 · HL · contact PI
Core A - Clinical Database.$343,570
P01 · FY2021 · CA · contact PI
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.$169,644
UG1 · FY2021 · HL · contact PI
Core A - Biospecimen Processing.$139,500
P50 · FY2021 · CA · contact PI
Core A - Clinical Database.$336,776
P01 · FY2020 · CA · contact PI
Core A - Biospecimen Processing.$179,433
P50 · FY2020 · CA · contact PI
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.$172,650
UG1 · FY2020 · HL · contact PI
Core A - Clinical Database.$185,917
P01 · FY2019 · CA · contact PI
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.$175,863
UG1 · FY2019 · HL · contact PI
Core A - Biospecimen Processing.$175,587
P50 · FY2019 · CA · contact PI
Core A - Biospecimen Processing.$188,424
P50 · FY2018 · CA · contact PI
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.$170,474
UG1 · FY2018 · HL · contact PI
Clinical Database$139,297
P01 · FY2018 · CA · contact PI
Core A - Biospecimen Processing.$6,631
P50 · FY2018 · CA · contact PI
Clinical Database$258,322
P01 · FY2017 · CA · contact PI
Biospecimen Processing$182,655
P50 · FY2017 · CA · contact PI
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.$148,895
UG1 · FY2017 · HL · contact PI
Clinical Database$268,229
P01 · FY2016 · CA · contact PI
Biospecimen Processing$171,695
P50 · FY2016 · CA · contact PI
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization$157,320
U10 · FY2016 · HL · contact PI
Clinical Database$267,575
P01 · FY2015 · CA · contact PI
Biospecimen Processing$212,656
P50 · FY2015 · CA · contact PI
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization$157,320
U10 · FY2015 · HL · contact PI
Clinical Database$258,926
P01 · FY2014 · CA · contact PI
Biospecimen Processing$212,787
P50 · FY2014 · CA · contact PI
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization$157,320
U10 · FY2014 · HL · contact PI
Clinical Database$266,311
P01 · FY2013 · CA · contact PI
Biospecimen Processing$209,445
P50 · FY2013 · CA · contact PI
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization$157,320
U10 · FY2013 · HL · contact PI
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization$157,320
U10 · FY2012 · HL · contact PI
Clinical Database$153,762
P01 · FY2012 · CA · contact PI
Clinical Database$258,579
P01 · FY2011 · CA · contact PI
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization$150,480
U10 · FY2011 · HL · contact PI
Clinical Database$145,310
P01 · FY2010 · CA · contact PI
Clinical Database$143,825
P01 · FY2009 · CA · contact PI
Clinical Database$141,893
P01 · FY2008 · CA · contact PI
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO$134,325
K08 · FY2003 · HL
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO$134,325
K08 · FY2002 · HL
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO$99,360
K08 · FY2001 · HL
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO$17,784
K08 · FY2001 · HL
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO$114,519
K08 · FY2000 · HL